Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. The deal with CVS is the latest this week as Novo Nordisk pushes ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The company also taking a hit after CVS announced a deal with Novo Nordisk, making Wegovy its preferred weight loss drug and dropping Eli Lilly's Mounjaro. Speaking of CVS, shares are rising after ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...